Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice

Idiopathic pulmonary fibrosis (IPF) seriously threatens human life and health, and no curative therapy is available at present. Nintedanib is the first agent approved by the US Food and Drug Administration (FDA) in order to treat IPF; however, its mechanism of inhibition of IPF is still elusive. Acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Lin, Cheng, Yiju, Yang, Wenting, Wu, Xiao, Zhu, Honglan, Hu, Meigui, Zhang, Yuquan, Zhang, Menglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359208/
https://www.ncbi.nlm.nih.gov/pubmed/37160579
http://dx.doi.org/10.1007/s10753-023-01825-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359208/
https://www.ncbi.nlm.nih.gov/pubmed/37160579
http://dx.doi.org/10.1007/s10753-023-01825-2

Ejemplares similares